Black Canyon Bio
Developer of precision cancer immunotherapies based on a specific neoantigen-targeted peptide technology platform. The organization focuses on discovery and credentialing of tumor neoantigens, preclinical and translational development, early-phase clinical advancement of peptide vaccine candidates, biomarker qualification, and supporting regulatory and commercial activities to advance therapies for solid tumors and virus-associated cancers.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Peptide cancer vaccine candidate for virus-associated cancers (lead program)
A peptide-based cancer vaccine candidate targeting neoantigens associated with virus-linked tumors. Identified as the lead program with planned clinical testing in 2026.
Specific neoantigen peptide technology platform
Platform technology enabling identification and credentialing of tumor-specific neoantigens to support personalized peptide vaccine development.
Peptide cancer vaccine candidate for virus-associated cancers (lead program)
A peptide-based cancer vaccine candidate targeting neoantigens associated with virus-linked tumors. Identified as the lead program with planned clinical testing in 2026.
Specific neoantigen peptide technology platform
Platform technology enabling identification and credentialing of tumor-specific neoantigens to support personalized peptide vaccine development.
Services
Management and execution of translational research and preclinical studies to advance therapeutic candidates toward clinical entry.
Qualification and validation of biomarkers and pharmacodynamic assays for incorporation into clinical protocols.
Preparation of regulatory documentation and support for regulatory affairs including FDA submission materials.
Advisory services for corporate finance, fundraising, strategic partnerships and transaction due diligence.
Management and execution of translational research and preclinical studies to advance therapeutic candidates toward clinical entry.
Qualification and validation of biomarkers and pharmacodynamic assays for incorporation into clinical protocols.
Preparation of regulatory documentation and support for regulatory affairs including FDA submission materials.
Advisory services for corporate finance, fundraising, strategic partnerships and transaction due diligence.
Expertise Areas
- Neoantigen vaccine development
- Translational and preclinical development
- Early-phase clinical development
- Biomarker discovery and qualification
Key Technologies
- Neoantigen-targeted peptide vaccines
- Peptide design and synthesis
- Bioinformatics for antigen identification
- Molecular engineering
News & Updates
The lead peptide cancer vaccine program for virus-associated cancers is scheduled to begin clinical testing in 2026.
The lead peptide cancer vaccine program for virus-associated cancers is scheduled to begin clinical testing in 2026.